Abstract：OBJECTIVE: Andrographolide, the active component in andrographis paniculata, has potent anti-inflammatory actions. This study aimed to evaluate the effects of andrographolide on eosinophil granulocytes (EOS) and the expression of eotaxin and IL-5 in mice with asthma. METHODS: BALB/c mice were randomly assigned into normal control, asthma, budesonide treatment and andrographolide treatment groups (n=8 each). Mice in the latter three groups were sensitized and challenged with ovalbumin (OVA) to induce asthma. ELISA was used to detect the concentrations of eotaxin and IL-5 in bronchoalveolar lavage fluid (BALF) and peripheral blood. The expression of eotaxin mRNA and IL-5 mRNA in lung tissues was detected by real-time quantitative PCR. RESULTS: Andrographolide treatment significantly decreased EOS count in BALF (P<0.05) and the effect of andrographolide was better than the effect of budesonide. Andrographolide treatment significantly down-regulated the expression of eotaxin and IL-5 in BALF, lung eotaxin mRNA expression and blood IL-5 expression (P<0.05), but the effects of andrographolide were poorer than the effects of budesonide. Andrographolide treatment resulted in a decrease in blood eotaxin expression and lung IL-5 mRNA expression and the effects of andrographolide were similar to budesonide. CONCLUSIONS: Andrographolide can down-regulate the expression of IL-5 and eotaxin and thus suppress the inflitration of EOS in a mouse model of asthma.
LI Yan-Hua,WANG Mei-Yi,JIN Rong et al. Effects of andrographolide on the expression of eosinophil granulocytes and possible mechanisms[J]. CJCP, 2012, 14(5): 371-374.
［1］Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma［J］. N Engl J Med, 2009, 360(10): 973-984.
［2］Bao Z, Guan S, Cheng C, Wu S, Wong SH, Kemeny DM, et al. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-kappaB pathway［J］. Am J Respir Crit Care Med, 2009, 179(8): 657-665.
［3］Park SJ, Lee KS, Kim SR, Min KH, Choe YH, Moon H, et al. Peroxisome proliferator-activated receptor gamma agonist down-regulates IL-17 expression in a murine model of allergic airway inflammation［J］. J Immunol, 2009, 183(5): 32593267.
［4］Huang JJ, Joh JW, Fuentebella J, Patel A, Nguyen T, Seki S, et al. Eotaxin and FGF enhance signaling through an extracellular signal-related kinase (ERK)-dependent pathway in the pathogenesis of eosinophilic esophagitis［J］. Allergy Asthma Clin Immunol, 2010, 6(1): 25.
［5］Barnes PJ. New therapies for asthma: is there any progress?［J］. Trends Pharmacol Sci, 2010, 31(7): 335-343.
［6］Hamid Q, Tulic M. Immunobiology of asthma［J］. Annu Rev Physiol, 2009, 71: 489-507.
［7］Queto T, Gaspar-Elsas MI, Masid-de-Brito D, Vasconcelos ZF, Ferraris FK, Penido C, et al. Cysteinyl-leukotriene type 1 receptors transduce a critical signal for the up-regulation of eosinophilopoiesis by interleukin-13 and eotaxin in murine bone marrow［J］. J Leukoc Biol, 2010, 87(5): 885-893.
［10］Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide［J］. Int Immunopharmacol, 2009, 9(3): 313-318.
［11］Chandrasekaran CV, Gupta A, Agarwal A. Effect of an extract of Andrographis paniculata leaves on inflammatory and allergic mediators in vitro［J］. J Ethnopharmacol, 2010, 129(2): 203-207.
［12］Dougherty RH, Fahy JV. Acute exacerbations of asthma: epidemiology, biologyand the exacerbation-prone phenotype［J］. Clin Exp Allergy, 2009, 39(2): 193-202.
